drug
balsalazide disodium
Marketedupdated 5mo agoby Carnegie Pharmaceuticals LLC
Approvedcommunity read0 votes
indications
investigational
IBD (Crohn's + UC)
all catalysts(0)
nothing on the calendar yet
Trials studying balsalazide disodium
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 24, 2027
143 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Jun 23, 2031method-of-use (U-1229)US 84972564.7y
- Feb 24, 2027patentUS 7452872*PED143d
- Feb 24, 2027patentUS 7625884*PED143d
- Aug 24, 2026method-of-use (U-1229)US 7452872
- Aug 24, 2026method-of-use (U-141)US 7452872
- Aug 24, 2026method-of-use (U-1229)US 7625884
- Aug 24, 2026method-of-use (U-141)US 7625884
- Aug 2, 2026method-of-use (U-1229)US 9192616
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that